Key result
Sympathetic blockade remains valuable for managing hypertension, controlling AF heart rate, and improving HF.
Why the study?
Does sympathetic blockade improve clinical outcomes in patients with various cardiovascular diseases?
Does sympathetic blockade improve clinical outcomes in patients with various cardiovascular diseases?
Sympathetic blockade continues to be a crucial therapeutic strategy across multiple cardiovascular conditions, particularly heart failure, hypertension, and atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Supports sympathetic blockade across hypertension, AF, and HF; leaves open prospective RCTs in contemporary populations.
INTRODUCTION: A dysregulated sympathetic nervous system is a major factor in the development and progression of cardiovascular disease; thus, understanding the mechanism and function of the sympathetic nervous system and appropriately regulating sympathetic activity to treat various cardiovascular diseases are crucial. Areas covered: This review focused on previous studies in managing hypertension, atrial fibrillation, coronary artery disease, heart failure, and perioperative management with sympathetic blockade. We reviewed both pharmacological and non-pharmacological management. Expert commentary: Chronic sympathetic nervous system activation is related to several cardiovascular diseases mediated by various pathways. Advancement in measuring sympathetic activity makes visualizing noninvasively and evaluating the activation level even in single fibers possible. Evidence suggests that sympathetic blockade still has a role in managing hypertension and controlling the heart rate in atrial fibrillation. For ischemic heart disease, beta-adrenergic receptor antagonists have been considered a milestone drug to control symptoms and prevent long-term adverse effects, although its clinical implication has become less potent in the era of successful revascularization. Owing to pathologic involvement of sympathetic nervous system activation in heart failure progression, sympathetic blockade has proved its value in improving the clinical course of patients with heart failure.
No takes yet. Share an insight, caveat, or question.
Park et al. (2017) conducted a review in Cardiovascular disease. Sympathetic blockade was evaluated. Sympathetic blockade remains valuable in managing hypertension, controlling heart rate in atrial fibrillation, and improving the clinical course of patients with heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: